Ruti Aga: A Knee-Injection Prescription, Three Failed Verifications, and Six Years

A half marathon in March, in China. Ruti Aga won it. The in-competition sample from that same race became the most expensive object of her career. The statement the Athletics Integrity Unit (AIU) released on Thursday does not trace the six-year ban to a doping syndicate; it traces it to a piece of paper — a knee-treatment prescription that was not real. My habit is fixed: when a medical document enters the public record, I read its date first, then its author, and only then the condition it describes. In this case the order collapsed. First we learned the prescription existed; then that the clinic named on it did not; then that the "doctor" was a family member with no medical registration, who explained the document by claiming he kept "an old prescription pad from a former workplace" — a pad the clinic explicitly disowns. Three frames before the fall, the stumble had already begun. It was on paper, not on the road. Ruti Aga is a 32-year-old Ethiopian marathoner. The AIU release gives no mark, no split, no field strength. My own race notes carry the March 2026 Tokyo Marathon title and three second places at World Marathon Majors, with a best in the 2:18–2:20 band. Those numbers come from race records, not from the AIU statement, and I am putting that limit at the top of the piece rather than letting the numbers build a drama they cannot support. The sanction dates are clean. The provisional suspension ran from 10 September, and the six-year period will be counted from the same date. The statement does not give the year, so the arithmetic has to be carried with a condition attached: if that is 10 September of the current year, she returns at roughly 38. Against the depth of Ethiopian women's marathon running, a 38-year-old with a doping record is not a selection proposition. Six years on paper; a career sentence in practice. What the statement omits matters as much. No name for the March race, no time, no scope of disqualification, no confirmation of whether the result and prize money from that race are voided. Standard AIU practice disqualifies the competition at which the sample was collected and strips ranking points from that date forward, but since the release does not say so, I file it under inference, not fact. Now the part the coverage has got wrong. Several reports have called methylprednisolone a "prohibited steroid" and stated that WADA classes it as performance-enhancing. That is imprecise. It is a glucocorticoid — class S9 on the WADA Prohibited List — not an anabolic steroid (S1). And S9 carries a very specific condition: prohibited in-competition only, and only by injection, oral or rectal routes. The consequence is direct. A therapeutic knee injection given out-of-competition is entirely lawful. It becomes a violation only if residue is present inside the in-competition window — and a road race's testing window opens at 23:59 the night before, which is how an injection given days earlier gets caught. The case rested on route and timing, not on "steroid use." That is precisely where a defence existed. Intra-articular injection for knee synovitis is routine sports-medicine practice in distance runners; the mechanism is credible. Had the treatment been real, real records, a real date and a real route could have argued this down towards no-fault or no-significant-fault. Forging the prescription closed the one path that might have held. Three verifications, three failures. The clinic did not exist. The author had no registration. The "old pad" was disowned by the institution it supposedly came from. That is not a filing error; it is the signature of an athlete operating without a credentialed team physician. I mark that as inference, because the statement never says whether a team doctor was present — but when the only evidence of treatment is a forged document, the TUE pathway is visibly not running. The six-year total is internally consistent: two years for presence, four for tampering, the Code's standard sanction. The arithmetic tells us the panel rejected the no-significant-fault mitigation, and it tells us the forged document was treated as concealment intent without aggravating the presence charge. The four years belong to the paper, not the drug. At Russia 2026 I logged 32 team medical bulletins across 64 matches and catalogued 47 documented injury events. That exercise taught me to read injury as workplace risk rather than character flaw. Here the formula only half applies, and that is the honest finding. The knee was risk: chronic knee pathology is a known load-bearing failure mode in a 2:18–2:20 marathoner. The prescription was a decision, and decisions are sanctioned differently from risks. The Chinese label-race economy needs naming too. For East African marathoners, Asian label races between Majors are a lucrative, low-race-count income tier. That same tier is now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races, and the agent-clinic networks that supply medical support to these athletes are not built for that collision. Two things are being said almost everywhere, and both need correcting. Calling this a steroid case is convenient, not accurate; it distorts comparison, because a glucocorticoid has no proven endurance benefit and cannot be lined up against EPO or anabolic cases. And the "disproportionate enforcement against African road runners" argument is half true. Four of the six years are for the document. The bitter irony is that a substance with no proven endurance benefit drew six years because the cover story was false. The system punishes the cover story harder than the offence. One further caution, since I write from London, surrounded by British Athletics and UK Sport high-performance assumptions. It is easy to ask from that vantage point why a TUE was not obtained. The answer will not come from there. Ethiopian road racing runs on agent-clinic networks and private spending, not on lottery funding and full-time medical staff. Compare inputs and constraints, not just outputs. What to watch next. First, the CAS appeal window, typically around 21 days from the reasoned decision, and whether a document-based finding is challenged at all. Second, the disqualification scope: the March result, the prize money, the ranking points thereafter. Third, whether the agent or management is investigated — the AIU statement names only the family member, and whoever suggested or accepted that document remains unnamed. Fourth, the Ethiopian federation's position, on which the statement is silent. Fifth, and largest: whether label races make medical-document verification routine. My read is that the enforcement frontier has already moved from detection to document checking, because one informal medical network serves many athletes in the same training cluster. Every injury file I keep ends with the same question: who reads the scan first? Here it changes. Who reads the prescription first — the athlete herself, her agent, or an investigator months later? The day that question starts being asked of the medical staff before the athlete, cases like this one get rarer.